Valuation: ALLOVIRPAR

Market Cap 49.21M 44.13M 40.67M 36.94M 69.91M 4.61B 71.86M 487M 194M 2.47B 185M 181M 7.81B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -61.95M -57.09M -51.85M -98.13M -6.48B -101M -684M -272M -3.47B -259M -254M -10.97B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
Current month-80.94%
Current year-80.94%
3 years 1.87
Extreme 1.87
57.15
5 years 1.87
Extreme 1.87
535.21
10 years 1.87
Extreme 1.87
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -171M -157M -143M -270M -17.85B -278M -1.88B -751M -9.57B -715M -699M -30.24B -58.77M -52.7M -48.57M -44.11M -83.48M -5.51B -85.81M -582M -232M -2.95B -221M -216M -9.33B
Net Debt -157M -140M -129M -117M -222M -14.67B -229M -1.55B -617M -7.86B -587M -575M -24.85B -118M -106M -97.76M -88.79M -168M -11.09B -173M -1.17B -466M -5.94B -444M -435M -18.78B
Projected Income Statement - Annual - ALLOVIRPAR
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
12/11/26 USD 1.870 0.00%
10/11/26 USD 1.870 -18.70%
09/11/26 USD 2.300 -4.96%
06/11/26 USD 2.420 +2.54%
05/11/26 USD 2.360 +16.83%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock